Investor Relations

Eton Pharmaceuticals, Inc. is a commercial company focused on developing, acquiring, and commercializing high-potential therapies for the treatment of patients with rare diseases. We have a diversified pipeline of product candidates across multiple therapeutic areas, and a team with significant expertise in bringing products from clinical trials to patients with exceptional speed.

Volume :

Minimum 15 minutes delayed. Source: LSEG

News Releases
November 25, 2024
Amglidia® has been approved by the European Medicines Agency (EMA) and is commercially available in Europe Strong strategic fit with Eton’s existing pediatric endocrinology focus Amglidia has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) Potential New Drug
November 12, 2024
Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million , or $0.02 per diluted share Entered into an asset purchase agreement to acquire Increlex® (mecasermin injection) Q3 2024 product sales increased 40% over Q3 2023, representing 15 th straight quarter of sequential product
November 7, 2024
- Product has patent protection through 2043 - - Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025 - DEER PARK, Ill. , Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on